Oklahoma City, OK6 Active Studies

Fanconi Anemia Clinical Trials in Oklahoma City, OK

Find 6 actively recruiting fanconi anemia clinical trials in Oklahoma City, OK. Connect with local research sites and explore new treatment options.

6
Active Trials
4
Sponsors
3,885
Enrolling

Recruiting Fanconi Anemia Studies in Oklahoma City

About Fanconi Anemia Clinical Trials in Oklahoma City

Fanconi anemia is a rare genetic disorder that affects bone marrow, reducing production of all types of blood cells and increasing cancer susceptibility. It is associated with physical abnormalities and organ defects. Treatment includes blood transfusions, growth factors, and stem cell transplant.

There are currently 6 fanconi anemia clinical trials recruiting participants in Oklahoma City, OK. These studies are seeking a combined 3,885 participants. Research is being sponsored by Minneapolis Heart Institute Foundation, Northwell Health, University of Oklahoma and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Fanconi Anemia Clinical Trials in Oklahoma City — FAQ

Are there fanconi anemia clinical trials in Oklahoma City?

Yes, there are 6 fanconi anemia clinical trials currently recruiting in Oklahoma City, OK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Oklahoma City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Oklahoma City research site will contact you about next steps.

Are clinical trials in Oklahoma City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Oklahoma City studies also compensate for your time and travel.

What fanconi anemia treatments are being tested?

The 6 active trials in Oklahoma City are testing new therapies including novel drugs, biologics, and treatment approaches for fanconi anemia.

Data updated July 13, 2026 from ClinicalTrials.gov